Dexcom Inc [NASDAQ: DXCM] surged by $11.94 during the normal trading session on while it closed the day at $133.72. The company report on March 5, 2024 at 4:26 PM that Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter.
Stelo will be the first glucose biosensor in the US cleared for use without a prescription.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Indicated for use for people 18 years and older who are not using insulin therapy.
Dexcom Inc stock has also gained 17.07% of its value over the past 7 days. However, DXCM stock has inclined by 13.09% in the 3 months of the year. Over the past six months meanwhile, it has gained 33.28% and gained 7.76% year-on date.
The market cap for DXCM stock reached $51.55 billion, with 385.40 million shares outstanding and 377.42 million shares in the current float. Compared to the average trading volume of 2.94M shares, DXCM reached a trading volume of 9499360 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Dexcom Inc [DXCM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DXCM shares is $148.21 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DXCM stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Dexcom Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on May 30, 2023. While these analysts kept the previous recommendation, Raymond James raised their target price from $127 to $138. The new note on the price target was released on April 17, 2023, representing the official price target for Dexcom Inc stock. Previously, the target price had yet another raise to $142, while UBS analysts kept a Buy rating on DXCM stock.
The Average True Range (ATR) for Dexcom Inc is set at 3.99, with the Price to Sales ratio for DXCM stock in the period of the last 12 months amounting to 14.23. The Price to Book ratio for the last quarter was 24.91, with the Price to Cash per share for the same quarter was set at 7.07. Price to Free Cash Flow for DXCM in the course of the last twelve months was 100.70 with Quick ratio for the last quarter at 2.48.
DXCM stock trade performance evaluation
Dexcom Inc [DXCM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.07. With this latest performance, DXCM shares gained by 10.30% in over the last four-week period, additionally plugging by 33.28% over the last 6 months – not to mention a rise of 18.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DXCM stock in for the last two-week period is set at 71.63, with the RSI for the last a single of trading hit 80.10, and the three-weeks RSI is set at 66.37 for Dexcom Inc [DXCM]. The present Moving Average for the last 50 days of trading for this stock 122.61, while it was recorded at 122.92 for the last single week of trading, and 113.10 for the last 200 days.
Dexcom Inc [DXCM]: An insightful look at the core fundamentals
Dexcom Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.48 and a Current Ratio set at 2.84.
Earnings per share (EPS) analysis for Dexcom Inc [DXCM] stock
With the latest financial reports released by the company, Dexcom Inc posted 0.17/share EPS, while the average EPS was predicted by analysts to be reported at 0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DXCM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Dexcom Inc go to 33.40%.
Dexcom Inc [DXCM]: Institutional Ownership
The top three institutional holders of DXCM stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in DXCM stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in DXCM stock with ownership which is approximately 5.8325%.
